10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2012 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | |||
| (In Millions, except shares in Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Net Sales | $ 39,874 | 38,851 | 35,167 |
| Cost of products sold | 15,120 | 15,541 | 14,665 |
| Research and development | 4,322 | 4,129 | 3,724 |
| Acquired in-process and collaborations research and development | 288 | 672 | 313 |
| Selling, general and administrative | 12,059 | 12,757 | 10,376 |
| Total Operating Cost and Expenses | 31,789 | 33,099 | 29,079 |
| Operating Earnings | 8,085 | 5,752 | 6,088 |
| Interest expense | 592 | 530 | 553 |
| Interest (income) | (79) | (85) | (105) |
| Net loss on extinguishment of debt | 1,351 | ||
| Net foreign exchange (gain) loss | (8) | (50) | (11) |
| Other (income) expense, net | (34) | 159 | (62) |
| Earnings Before Taxes | 6,263 | 5,199 | 5,713 |
| Taxes on Earnings | 300 | 470 | 1,087 |
| Net Earnings | 5,963 | 4,728 | 4,626 |
| Basic Earnings Per Common Share (in dollars per share) | 3.76 | 3.03 | 2.98 |
| Diluted Earnings Per Common Share (in dollars per share) | 3.72 | 3.01 | 2.96 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,575,378 | 1,557,643 | 1,546,400 |
| Dilutive Common Stock Options and Awards (in shares) | 16,460 | 9,746 | 9,622 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,591,838 | 1,567,389 | 1,556,022 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 1,166 | 26,789 | 29,403 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2012 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Net Earnings | $ 5,962,920 | 4,728,449 | 4,626,172 |
| Foreign currency translation (loss) adjustments | (6,826) | (817,539) | (2,290,256) |
| Net actuarial (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $(276,076) in 2012, $(391,528) in 2011 and $(70,389) in 2010 | (864,935) | (510,444) | (59,447) |
| Unrealized (losses) gains on marketable equity securities, net of taxes of $(4,079) in 2012, $8,338 in 2011 and $61 in 2010 | (7,066) | 14,442 | 106 |
| Net adjustments for derivative instruments designated as cash flow hedges, net of taxes of $(29,417) in 2012, $19,857 in 2011 and $20,567 in 2010 | (117,666) | 83,202 | 128,677 |
| Other Comprehensive (loss) | (996,493) | (1,230,339) | (2,220,920) |
| Comprehensive Income | 4,966,427 | 3,498,110 | 2,405,252 |
| Supplemental Accumulated Other Comprehensive Income Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation loss (gain) adjustments | 79,353 | 72,527 | (745,012) |
| Net actuarial losses and prior service cost and credits | 3,595,554 | 2,730,619 | 2,220,175 |
| Cumulative unrealized (gains) on marketable equity securities | (31,363) | (38,429) | (23,987) |
| Cumulative (gains) on derivative instruments designated as cash flow hedges | (49,866) | (167,532) | (84,330) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2012 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 5,962,920 | 4,728,449 | 4,626,172 |
| Adjustments to reconcile earnings to net cash from operating activities - | |||
| Depreciation | 1,363,673 | 1,395,371 | 1,207,450 |
| Amortization of intangible assets | 1,419,534 | 1,648,523 | 1,416,855 |
| Share-based compensation | 433,114 | 382,602 | 387,183 |
| Acquired in-process and collaborations research and development | 288,000 | 672,500 | 313,200 |
| Investing and financing (gains) losses, net | 356,020 | 141,565 | 126,337 |
| Net loss on extinguishment of debt | 1,350,973 | ||
| Trade receivables | 35,996 | (670,152) | (394,665) |
| Inventories | (417,053) | (129,621) | 139,857 |
| Prepaid expenses and other assets | (35,298) | 413,266 | 553,145 |
| Trade accounts payable and other liabilities | (134,209) | 1,789,652 | 572,533 |
| Income taxes | (1,309,269) | (1,402,078) | (212,086) |
| Net Cash From Operating Activities | 9,314,401 | 8,970,077 | 8,735,981 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (1,227,473) | (672,500) | (9,433,243) |
| Acquisitions of property and equipment | (1,795,289) | (1,491,500) | (1,015,075) |
| Purchases of investment securities | (11,997,654) | (5,109,987) | (805,932) |
| Proceeds from sales of investment securities | 8,936,406 | 5,648,720 | 954,361 |
| Release of (deposit of) restricted funds | 1,870,000 | (1,870,000) | |
| Other | 2,722 | 16,099 | (18,426) |
| Net Cash (Used in) From Investing Activities | (6,081,288) | 260,832 | (12,188,315) |
| Cash Flow From (Used in) Financing Activities: | |||
| Proceeds from issuance of (repayments of) short-term debt and other | 783,868 | (1,964,685) | (203,854) |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 14,700,000 | 1,000,000 | 4,000,000 |
| Repayments of long-term debt and debt with maturities over 3 months | (11,071,178) | (3,012,426) | (1,673,998) |
| Purchases of common shares | (2,364,240) | (77,007) | (866,825) |
| Proceeds from stock options exercised, including income tax benefit | 1,850,454 | 968,759 | 328,411 |
| Dividends paid | (3,182,811) | (2,938,096) | (2,671,475) |
| Net Cash From (Used in) Financing Activities | 716,093 | (6,023,455) | (1,087,741) |
| Effect of exchange rate changes on cash and cash equivalents | 40,137 | (43,005) | (620,893) |
| Net Increase (Decrease) in Cash and Cash Equivalents | 3,989,343 | 3,164,449 | (5,160,968) |
| Cash and Cash Equivalents, Beginning of Year | 6,812,820 | 3,648,371 | |
| Cash and Cash Equivalents, End of Year | 10,802,163 | 6,812,820 | 3,648,371 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,366,581 | 1,781,602 | 809,710 |
| Interest paid | 575,895 | 544,559 | 580,168 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2012 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2012 10-K (Filed: Feb 15, 2013) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2012 | Dec 31, 2011 | |
| Current Assets: | ||
| Cash and cash equivalents | $ 10,802,163 | 6,812,820 |
| Investments, primarily bank time deposits and U.S. treasury bills | 4,371,821 | 1,284,539 |
| Trade receivables, less allowances of - 2012: $405,921; 2011: $420,579; 2010: $388,564 | 7,612,860 | 7,683,920 |
| Inventories: | ||
| Finished products | 2,345,455 | 2,220,527 |
| Work in process | 628,874 | 432,358 |
| Materials | 817,984 | 631,364 |
| Total inventories | 3,792,313 | 3,284,249 |
| Deferred income taxes | 2,986,216 | 2,700,540 |
| Other prepaid expenses and receivables | 1,757,210 | 2,002,706 |
| Total Current Assets | 31,322,583 | 23,768,774 |
| Investments | 273,595 | 378,225 |
| Property and Equipment, at Cost: | ||
| Land | 604,462 | 633,917 |
| Buildings | 4,259,240 | 4,467,387 |
| Equipment | 13,110,833 | 12,216,388 |
| Construction in progress | 954,352 | 698,873 |
| Property and Equipment, at Cost | 18,928,887 | 18,016,565 |
| Less: accumulated depreciation and amortization | 10,865,840 | 10,142,610 |
| Net Property and Equipment | 8,063,047 | 7,873,955 |
| Intangible Assets, net of amortization | 8,588,285 | 9,989,636 |
| Goodwill | 15,774,127 | 15,705,380 |
| Deferred Income Taxes and Other Assets | 3,213,307 | 2,560,923 |
| Total Assets | 67,234,944 | 60,276,893 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 2,081,839 | 2,347,859 |
| Trade accounts payable | 1,796,990 | 1,721,127 |
| Salaries, wages and commissions | 1,427,765 | 1,260,121 |
| Other accrued liabilities | 6,787,995 | 7,854,994 |
| Dividends payable | 221,340 | 754,284 |
| Income taxes payable | 655,424 | 514,947 |
| Current portion of long-term debt | 308,823 | 1,026,896 |
| Total Current Liabilities | 13,280,176 | 15,480,228 |
| Long-term Debt | 18,085,302 | 12,039,822 |
| Post-employment Obligations and Other Long-term Liabilities | 9,056,234 | 8,230,698 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2012: 1,675,930,484; 2011: 1,638,870,201; 2010: 1,619,689,876 | 11,754,552 | 9,817,134 |
| Common shares held in treasury, at cost - Shares: 2012: 99,262,992; 2011: 68,491,382; 2010: 72,705,928 | (5,590,909) | (3,687,478) |
| Earnings employed in the business | 24,150,996 | 20,907,362 |
| Accumulated other comprehensive income (loss) | (3,593,678) | (2,597,185) |
| Total Abbott Shareholders' Investment | 26,720,961 | 24,439,833 |
| Noncontrolling Interests in Subsidiaries | 92,271 | 86,312 |
| Total Shareholders' Investment | 26,813,232 | 24,526,145 |
| Total Liabilities and Shareholders' Investment | 67,234,944 | 60,276,893 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2012 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |